Alx Oncology Holdings (ALXO) Interest Coverage Ratio (2019 - 2026)
Alx Oncology Holdings (ALXO) posted Interest Coverage Ratio of 4.94 for Q1 2026, up 91.77% sequentially from 60.11 in Q4 2025, and up 93.69% YoY from 2.55 in Q1 2025.
Powered by 
Analysis
Alx Oncology Holdings (ALXO) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Interest Coverage Ratio for 8 years, with the latest figure at 4.94 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 93.69% year-over-year to 4.94 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.77 (up 70.06% YoY) and the FY2025 annual result came in at 0.69, up 96.59% from the prior year.
- Interest Coverage Ratio grew to 4.94 in Q1 2026 per ALXO's latest filing, from 60.11 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 4.94 in Q1 2026 and troughed at 18340.5 in Q3 2022.
- A 5-year average of 2144.28 and a median of 83.21 in 2023 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2023: Interest Coverage Ratio sank 96919.77% in 2022, then jumped 99.41% in 2023.
- Over 5 years, Interest Coverage Ratio stood at 139.48 in 2022, then surged by 45.69% to 75.75 in 2023, then grew by 7.94% to 69.73 in 2024, then grew by 13.8% to 60.11 in 2025, then soared by 91.77% to 4.94 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 4.94, 60.11, and 55.23 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 1.42 |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -0.08 |
| 10 | Alx Oncology Holdings | 273.99 Mn | 273.99 Mn | - | -63.27 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -63.27 |
| Mar 31, 2026 | -57.30 |
| Dec 31, 2025 | -60.11 |
| Sep 30, 2025 | -55.23 |
| Jun 30, 2025 | -65.80 |
| Mar 31, 2025 | -78.37 |
| Dec 31, 2024 | -71.69 |
| Sep 30, 2024 | -73.02 |
| Jun 30, 2024 | -96.79 |
| Mar 31, 2024 | -88.44 |
| Dec 31, 2023 | -115.72 |
| Sep 30, 2023 | -136.25 |
| Jun 30, 2023 | -98.86 |
| Mar 31, 2023 | -83.21 |
| Dec 31, 2022 | -139.48 |
| Sep 30, 2022 | -18,340.50 |
| Jun 30, 2022 | -16,894.50 |
| Mar 31, 2022 | -8,249.00 |
| Dec 31, 2020 | 3,565.00 |
| Sep 30, 2020 | -88.37 |